Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by AstraZeneca < Previous 1 2 3 4 5 6 Next > IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial June 25, 2024 From AstraZeneca Via Business Wire Tickers AZN IMFINZI® (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer June 17, 2024 From AstraZeneca Via Business Wire Tickers AZN CALQUENCE® (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial June 16, 2024 From AstraZeneca Via Business Wire Tickers AZN FARXIGA approved in the US for the treatment of pediatric type-2 diabetes June 12, 2024 From AstraZeneca Via Business Wire Tickers AZN TAGRISSO® (osimertinib) granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer June 10, 2024 From AstraZeneca Via Business Wire Tickers AZN TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial June 02, 2024 From AstraZeneca Via Business Wire Tickers AZN IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo June 02, 2024 From AstraZeneca Via Business Wire Tickers AZN ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy June 02, 2024 From AstraZeneca Via Business Wire Tickers AZN Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial May 27, 2024 From AstraZeneca Via Business Wire Tickers AZN AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA) May 23, 2024 From AstraZeneca Via Business Wire Tickers AZN AstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024 May 22, 2024 From AstraZeneca Via Business Wire Tickers AZN AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030 May 21, 2024 From AstraZeneca Via Business Wire Tickers AZN New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease May 19, 2024 From AstraZeneca Via Business Wire Tickers AZN CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial May 02, 2024 From AstraZeneca Via Business Wire Tickers AZN AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio May 01, 2024 From AstraZeneca Via Business Wire Tickers AZN ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow April 29, 2024 From AstraZeneca Via Business Wire Tickers AZN Q1 2024 results April 25, 2024 From AstraZeneca Via Business Wire Tickers AZN IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial April 16, 2024 From AstraZeneca Via Business Wire Tickers AZN FASENRA approved for treatment of children aged 6 to 11 with severe asthma April 11, 2024 From AstraZeneca Via Business Wire Tickers AZN ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors April 05, 2024 From AstraZeneca Via Business Wire Tickers AZN IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial April 05, 2024 From AstraZeneca Via Business Wire Tickers AZN Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer April 02, 2024 From AstraZeneca Via Business Wire Tickers AZN AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer March 19, 2024 From AstraZeneca Via Business Wire Tickers AZN AstraZeneca caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolio March 18, 2024 From AstraZeneca Via Business Wire Tickers AZN AstraZeneca announces initiation of THARROS – a Phase III clinical trial investigating the potential of BREZTRI to improve cardiopulmonary outcomes in people with COPD March 13, 2024 From AstraZeneca Via Business Wire Tickers AZN MANDARA Phase III data published in New England Journal of Medicine show remission is an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with FASENRA February 23, 2024 From AstraZeneca Via Business Wire Tickers AZN Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated advanced nonsquamous non-small cell lung cancer February 19, 2024 From AstraZeneca Via Business Wire Tickers AZN TAGRISSO® (osimertinib) demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial February 19, 2024 From AstraZeneca Via Business Wire Tickers AZN TAGRISSO® (osimertinib) with the addition of chemotherapy approved in the US for patients with EGFR-mutated advanced lung cancer February 16, 2024 From AstraZeneca Via Business Wire Tickers AZN AstraZeneca Full year and Q4 2023 Financial Results February 08, 2024 From AstraZeneca Via Business Wire Tickers AZN < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.